Amgen Down Over 13%, Worst Performer in the DJIA and Nasdaq 100 So Far Today — Data Talk
Amgen Inc. (AMGN) is currently at $298.03, down $13.26 or 4.26%
--On pace for largest percent decrease since Feb. 7, 2024, when it fell 6.39%
--Snaps a three day winning streak
--Up 3.48% year-to-date
--Down 8.17% from its all-time closing high of $324.56 on Feb. 1, 2024
--Up 27.03% from 52 weeks ago (May 8, 2023), when it closed at $234.62
--Down 8.17% from its 52-week closing high of $324.56 on Feb. 1, 2024
--Up 39.09% from its 52-week closing low of $214.27 on June 1, 2023
--Traded as low as $297.52
--Down 4.42% at today's intraday low; largest intraday percent decrease since Feb. 7, 2024, when it fell as much as 6.58%
--Worst performer in the DJIA today
--Second worst performer in the S&P 500 today
--Worst performer in the Nasdaq 100 today
--Subtracted 87.11 points from the DJIA so far today
All data as of 12:01:03 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
May 06, 2024 12:20 ET (16:20 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
What’s Happening In the Markets This Week
-
What Does Nvidia’s Stock Split Mean for Investors?
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
The Most Attractive Investment Opportunities in Oil & Gas
-
Apple: Generative AI Strategy Should Drive Sales and Upgrades
-
2 Undervalued Stocks That Just Raised Dividends
-
2 Popular Stocks That Top Managers Are Selling
-
The Best REITs to Buy
-
Nio Earnings: Revenue and Loss Largely In Line, but Vehicle Margin Missed Amid Price Competition
-
The Best Biotech Stocks to Buy
-
After Earnings, Is Marvell Stock a Buy, a Sell, or Fairly Valued?